Background-The safety and efficacy of different types of ␤-blocker therapy in patients with non-dialysis-dependent chronic kidney disease (CKD) and systolic heart failure (HF) are not well described. We assessed whether treatment of systolic HF with carvedilol is efficacious and safe in adults with CKD. Methods and Results-We performed a post hoc analysis of pooled individual patient data (nϭ4217) from 2 multinational, 
This coexistence of CKD and HF could result in significant adverse interactive effects. 17 Indeed, the presence of CKD in HF patients is associated with an increased risk of hospitalization and death from pump failure and all-cause mortality 14 -16,18 independent of the degree of impairment in left ventricular ejection fraction (LVEF) 19 or the severity of heart failure based on New York Heart Association (NYHA) class. 20 Conversely, HF and its treatment can also increase the rate of progression in CKD. 5, 14, 17 The excess mortality in HF patients in the presence of CKD is likely to be multifactorial 17 and may include low utilization rates of currently available therapeutic options either due to lack of proven efficacy, 21, 22 lack of randomized, controlled studies, 11, 23 or concerns over the increased rates of adverse events, as has been demonstrated with the use of other agents such as angiotensin-converting enzyme inhibitors (ACE-I), 24 spironolactone, 25 and nesiritide. 26 Consequently, patients with the combination of HF and CKD are less likely to be treated with established HF therapies. 21, 27 ␤-Blockers are a cornerstone of therapy for HF, but their use in patients with HF and different degrees of CKD have not been thoroughly evaluated in randomized studies. 21 Carvedilol is a nonselective vasodilating ␤-adrenergic blocker with ␣ 1 adrenergic-blocking activities 28, 29 with established efficacy in decreasing mortality and morbidity in patients with mild to severe chronic HF with systolic left ventricular dysfunction (LVD). 30, 31 Carvedilol decreases systolic and diastolic blood pressure without a decrease in renal blood flow or GFR while reducing renal vascular resistance. 32 These hemodynamic effects of carvedilol could be particularly beneficial in patients with CKD. 33 Although a small, randomized study demonstrated that carvedilol improved survival in chronic dialysis patients with severe HF 34 and other studies have failed to demonstrate a benefit of other ␤-blockers in the dialysis population, 35 there remains a paucity of data from randomized studies evaluating the efficacy and safety of carvedilol therapy in the presence of CKD. We therefore conducted a post hoc meta-analysis of the CKD subgroup among 4217 patients enrolled in 2 placebocontrolled randomized studies of carvedilol therapy in patients with different types of systolic LVD with or without symptomatic HF. 30, 31 
Methods
We analyzed the pooled patient-level data from 2 large, multicenter, multinational, double-blind, randomized, placebo-controlled studies of carvedilol in systolic LVD with or without symptoms of HF. 30, 31 These studies were similar with respect to the study design, dose titration of carvedilol, primary and secondary outcomes, and duration of the follow-up. Briefly, CAPRICORN (Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study) randomly assigned 1959 patients within 21 days after acute myocardial infarction with LVEF Յ0.40 with or without symptomatic HF to either carvedilol (nϭ975) or placebo (nϭ984). 30 In the COPERNICUS (Carvedilol Prospective Randomized, Cumulative Survival) study, a total of 2289 patients with LVEF Յ0.25 and severe chronic HF of ischemic or nonischemic etiology while on standard therapy were randomly assigned to carvedilol (nϭ1156) and to placebo (nϭ1143). 31 For CAPRICORN, carvedilol was initiated at 6.25 mg twice daily within 21 days of the acute myocardial infarction and progressed to 12.5 mg twice per day within 3 to 10 days, with further escalation to the target dose of 25 mg twice per day (maximum dose) within another 5 to 10 days as tolerated. For COPERNICUS, carvedilol was initiated at 3.125 mg twice per day and titrated at intervals of no less than 2 weeks to 12.5 mg twice daily with further escalation to the target 
Definition of CKD
We used the 4 variable Modification of Diet in Renal Disease formula to estimate the eGFR expressed in mL/min/1.73 m 2 , 4 based on the serum creatinine values at the time of enrollment. This formula has been previously used in several HF studies. 5, 7, 18, 27, 36, 37 CKD and non-CKD groups were defined on the basis of eGFR values of Յ60 mL/min/1.73 m 2 , respectively. As a sensitivity analysis, we assessed the efficacy of carvedilol in those with eGFR Ͻ45 mL/min/1.73 m 2 (CKD stage 3b) and eGFR Ն45 to 60 mL/min/ 1.73 m 2 (CKD stage 3a).
Primary and Secondary Outcomes
The primary outcome in this analysis was all-cause mortality. Secondary outcomes were cardiovascular mortality, HF mortality, first hospitalization for HF, composite of cardiovascular mortality or hospitalization for HF, and sudden cardiac death. The outcomes in the present analysis were identical to those specified in the original protocols. 30, 31 Clinical outcomes were adjudicated by the end point committees for the respective studies.
Statistical Methods
The data from the individual patients who participated in the CAPRICORN and COPERNICUS trials were pooled for the present analysis. Baseline characteristics were summarized descriptively using summary statistics according to the variable distribution (ie, mean and standard deviation for continuous variables; frequencies for categorical variables). Analysis of the time to each end point was performed using Cox proportional hazards regression. For all the end points considered, the null hypothesis assumed that carvedilol therapy was similar to placebo in HF patients with concomitant CKD (eGFR Յ60 mL/min/ 1.73 m 2 ). The same hypothesis was tested for the non-CKD (Ͼ60 mL/min/1.73 m 2 ) subgroup. The following covariates were considered in the CKD subgroup analyses of these end points: baseline age (Ն65 versus Ͼ 65 years), sex, race (Caucasian, African American, others), LVEF (Ͻ20% versus Ն20%), and NYHA classification. Other covariates included history (yes or no) of diabetes mellitus, hypertension, coronary artery bypass graft, percutaneous coronary angioplasty, and stroke; and use (yes or no) of ACE-I or angiotensin-receptor blockers, spironolactone, digitalis, and diuretics.
Initially for each end point, covariates were evaluated one by one, with treatment arm and study type in the model. Treatment by study and treatment by covariate interactions were explored sequentially in this model. Main effects were tested at the 0.05 level and interactions at a 0.10 level. If the covariate or interaction effect was not significant, it was dropped and not included in the main analysis with treatment and study effect in the CKD subgroups (parsimonious model).
Additionally, to verify the robustness of the treatment effect, for each end point, CKD subgroup analyses models were examined that included: age (Յ65 versus Ͼ65 years), sex, race (Caucasian, African American, others), diabetes mellitus (yes or no), LVEF (Ͻ20% versus Ն20%), treatment arm, and study type. These covariates were selected because of prior evidence suggesting their association with outcomes in congestive HF as well as in CKD. When compared with a parsimonious model including only treatment arm and study type, the treatment effect observed in these subgroup analyses models was nearly identical. As such, primary inferences in the CKD subgroup analyses for these end points were based on the parsimonious models.
Finally, a sensitivity analysis was performed in the subgroups with eGFR Ͻ45 mL/min/1.73 m 2 (CKD stage 3b) and eGFR Ն45 to 60 mL/min/1.73 m 2 (CKD stage 3a). These sensitivity analyses models included treatment arm and study type.
All analyses were performed with SAS, version 8.2 (SAS institute, Inc, Cary, NC).
Results

Baseline Characteristics of the Cohort
A total of 4217 subjects were included in this analysis. The mean (ϮSD) eGFR was 57.2 (Ϯ18.7) mL/min/1.73 m 2 .
The eGFR values at baseline as well as at the last follow-up were similarly distributed in the carvedilol and placebo groups (Figure) . CKD was present in 2566 of 4217 (60.8%) of all patients enrolled in these 2 trials. Among individuals with ¶NYHA classification was not captured for the patients enrolled in the COPERNICUS study. Hence, this classification is given for the cohort of CAPRICORN study participants.
CKD, 1293 (50.4%) were randomly assigned to carvedilol therapy and 1273 (49.6%) to placebo. There were 1651(39.2%) non-CKD patients at baseline. Of these, 822 (49.8%) received carvedilol.
Baseline characteristics of the patients are summarized in Table 1 and in Supplemental Table 1 . In both CKD strata, comorbidities as well as the use of medications such as ACE-I or angiotensin-receptor blockers and anticoagulation therapy were similarly distributed in patients randomly assigned to carvedilol or placebo. Conversely, patients with CKD appeared older and to have more severe HF as assessed by NYHA classification than non-CKD individuals. In addition, a higher number of CKD patients were treated with a diuretic (84% versus 54%), digitalis (48% versus 28%), or spironolactone (14% versus 7%).
Overall Clinical Outcomes
The median and mean (ϮSD) duration of actual follow-up were 13.5 months and 13.6 (Ϯ7.9) months, respectively. Discontinuation of carvedilol was similarly frequent in CKD and non-CKD subgroups (24% versus 22%). The patients with CKD had increased rates of primary as well as secondary outcomes on univariate analysis (Table 2 ) and were further confirmed on multivariate analysis (data not shown).
Outcomes of Carvedilol Therapy
Random assignment to carvedilol decreased the risks for the primary as well as all secondary outcomes in both groups of patients (Table 3 and Table 4 Pϭ0.0980). The magnitude of the relative risk reduction in the incidence of the primary and secondary outcomes was similar in the CKD and non-CKD groups. For each clinical outcome, there were no statistically significant interactions observed between treatment (carvedilol, placebo) and study type (CAPRICORN, COPERNICUS).
Furthermore, the robustness of the treatment effect for each end point in the CKD subgroup remained consistent when other important covariates were added to the Cox models (Supplemental Table 2 ). The interaction between treatment and CKD group was nonsignificant for all outcomes.
A sensitivity analysis (Table 4 ) demonstrated that efficacy of carvedilol was not significantly different from placebo for the primary or secondary outcomes in the eGFR (Ͻ45 mL/min/1.73 m 2 , CKD stage 3b) subgroup. The overlapping confidence intervals for these outcomes in this subgroup of heart failure patients may be related to relatively small sample size (CKD 3b, carvedilol versus placebo: nϭ544 versus 572).
Investigator-reported adverse events were adjudicated by the end point committee and the rates of cardiac, neurologi- Event rates for primary and secondary outcomes All-cause mortality, n (%) 244 (12) 336 (16) 181 (14) 233 (18) 63 (8) 103 (13) Cardiovascular mortality, n (%) 218 (11) 301 (14) 162 (13) 209 (17) 56 (7) 92 (11) HF mortality, n (%) 118 (6) 174 (8) 97 (8) 139 (11) 21 (3) 35 (4.2) First hospitalizations for HF, n (%) 312 (15) 393 (18) 216 (17) 280 (22) 96 (12) 113 (14) Composite of cardiovascular mortality or hospitalization for HF, n (%)
453 (22) 573 (27) 315 (25) 401 (32) 138 (17) 172 (21) Sudden cardiac death, n (%) 96 (5) 136 (7) 67 (6) 87 (7) 29 (4) 49 (6) *Follow-up serum creatinine values were available for 1632 of 4217 (39%) of total patients.
cal, vascular, and other miscellaneous adverse events with the use of carvedilol compared with placebo in patients with CKD as well as non-CKD are presented in Table 5 . The cumulative incidence of transient changes in serum creatinine in the CKD (carvedilol versus placebo) patients was 4.6% versus 1.8% (PϽ0.001). However, none of these patients required dialysis therapy. The use of carvedilol was associated with an increase in the relative incidence of headache, orthostatic hypotension, hyperkalemia, and hyperglycemia in HF patients with CKD. The overall discontinuation rate of carvedilol was similar in the CKD and non-CKD subgroups (24% versus 22%).
Discussion
CKD is an independent risk factor for cardiovascular morbidity and mortality in patients with HF. [5] [6] [7] [8] [9] With the evolving epidemic of CKD and our aging population, the prevalence of patients with concomitant heart failure and CKD is increasing. 13 Hence, it is important to understand whether current standard therapies have a similar degree of efficacy and safety profiles in HF patients with different degrees of CKD. 11, 23 This post hoc analysis of patient-level data from 2 large, randomized, placebo-controlled studies with HF demonstrated that more than 60% of HF patients had mild to moderate CKD at the time of enrollment. Overall, treatment with carvedilol resulted in similar degrees of reduction in the relative risks for all-cause, cardiovascular, and HF mortality in the group of HF patients with CKD. As one would expect, this reduction translates to a greater absolute benefit with carvedilol in CKD patients.
To our knowledge, this is the first report in which individual patient data on a large cohort has been used to analyze the efficacy and safety of carvedilol in HF patients with concomitant CKD. The presence of CKD can worsen the systemic effects of HF via adverse effects on cardiac, hemodynamic, and neurohormonal adaptive (or maladaptive) responses, including increased sympathetic activity, and these could portend a poor prognosis. 6, 38, 39 Accordingly, different degrees of CKD are independently associated with an increased risk for all-cause mortality as well as HF progression. [5] [6] [7] [8] [9] In addition, the synergism between HF and CKD could also potentiate other risk factors frequently associated with mild to There was no significant interaction of treatment and CKD/non-CKD for any of the outcomes.
moderate degrees of CKD such as anemia 36, 40 and chronic inflammation. 41 In individuals without CKD, prolonged use of carvedilol has been shown to improve symptoms of HF, increase LVEF, mitigate neurohormonal activation and peripheral vasoconstriction, and decrease sympathetic overactivity as well as salt and water retention. 6, 38 These events may be particularly relevant in the setting of CKD, where carvedilol therapy could potentially improve renal hemodynamics and kidney function. Similarly, although the benefits of antioxidant properties of carvedilol are not fully understood, 42 it is possible that these properties may have a special role in patients with a combination of HF and substantial CKD.
In this study population, the addition of carvedilol to conventional HF therapy was generally well tolerated. The rate of discontinuation of carvedilol based on the investigatorreported adverse events was similar in both groups of patients. Changes in renal function without need for dialysis therapy were more frequent in the HF patients with concomitant CKD on treatment with carvedilol despite careful titration of carvedilol dose. Similar changes in kidney function have been reported with other types of HF therapy. 24 However, it is essential that HF patients with CKD when treated with carvedilol should be carefully monitored and dose optimization-tailored, based on individual patient responses in serum creatinine and/or eGFR values during the follow-up period. In addition, CKD patients are at increased risk for development of orthostatic hypotension, hyperkalemia, and hyperglycemia after carvedilol therapy; thus, careful monitoring for these events is clearly warranted.
These findings provide strong evidence to suggest that addition of carvedilol to the conventional HF therapy in CKD patients is beneficial and safe. Ghali et al 43 and Erdmann et al 44 demonstrated similar benefits with metoprolol and bisoprolol, respectively, in patients with HF and CKD. However, in a sensitivity analysis of HF patients with advanced CKD (stage 3b), the efficacy of carvedilol was not different from placebo. Whether this reflects a lack of sufficient power due to the relatively small sample size in the subgroup with advanced CKD or a different biological response to carvedilol in the setting of more advanced CKD cannot be determined in this post hoc analysis and merits additional studies.
This study has several limitations: First, almost all serum creatinine-based estimating equations for GFR are inherently imprecise, and this is specifically true when serum creatinine is measured in different laboratories or in those with lower than expected muscle mass. This is an important concern in patients with HF who may have lower muscle mass than those in the general population. Conversely, HF itself or therapy with ACE-I and diuretics may result in transient changes in GFR without concomitant changes in the underlying kidney function. 16 These issues could potentially have resulted in overestimation or underestimation of eGFR with misclassification of CKD stages. 45 Second, our analysis is a post hoc analysis of the original studies. We had the ability to analyze individual-level data from 2 randomized, doubleblind, placebo-controlled studies, with similar homogeneity in the study design, dose titration of carvedilol, and rigorous uniform definitions as well as rigorous ascertainment of prespecified outcomes. Nevertheless, our results should still be considered hypothesis forming and must be extrapolated cautiously to those with advanced CKD or severe HF. Third, this meta-analysis involved a homogenous population of systolic HF with a relatively low number of African Americans. Our population may not accurately represent the HF patient population in the community, and our results should be generalized cautiously to those not well represented in our analysis. 46 A number of strengths of our analysis are also worth noting. We analyzed a large number of patients with CKD and thus provide the most robust evidence to date to suggest that carvedilol therapy has beneficial effects in patients with mild to moderate CKD and HF. An additional randomized study with adequate sample size is needed to determine whether the benefits of carvedilol therapy extend to individuals with advanced CKD (eGFR Ͻ45 mL/min/1.73 m 2 ). Additionally, we analyzed results of treatment with carvedilol in both ischemic and nonischemic HF patients; hence, these results are generalizable to CKD patients with LVD of either etiology.
Conclusion
The results of this meta-analysis support treatment with carvedilol to reduce rates of all-cause mortality as well as other HF-related events in patients with LVD with or without symptomatic HF in the presence of mild to moderate CKD. The efficacy of carvedilol therapy in HF patients with advanced CKD has not been established.
